Abstract Integrin αvβ3, absent in most normal cells, has emerged as both a marker and a driver of tumor stemness and drug resistance in epithelial cancers, making it an attractive therapeutic target. The humanized IgG1 anti-αvβ3 antibody, etaracizumab, was originally developed to exploit NK cell-mediated cytotoxicity against αvβ3-positive tumors. However, despite its favorable safety profile and clinical efficacy, its impact was insufficient for further development. We previously discovered that αvβ3-positive epithelial tumors exhibit a tumor-associated macrophage (TAM)-rich microenvironment with limited NK cell infiltration, potentially limiting the effectiveness of etaracizumab. Here, we hypothesized that re-engineering the anti-αvβ3 antibody to activate TAM-mediated cytotoxicity would enhance its anti-tumor activity. We developed a fully human IgG4 variant of etaracizumab (anti-αvβ3 G4) with identical affinity for integrin αvβ3, but optimized for activation of CD64, an immune effector cell-activating receptor, selectively expressed on macrophages. In organotypic cultures of lung cancer patients and mouse xenografts, anti-αvβ3 G4 demonstrated superior anti-tumor activity compared to its IgG1 counterpart. Mechanistically, this enhancement was driven by CD64 activation in TAMs, leading to robust upregulation of inducible nitric oxide synthase (iNOS), a pivotal enzyme for immune effector-mediated cytotoxicity. Our findings reveal a powerful strategy for targeting highly aggressive, drug-resistant integrin αvβ3-positive tumors by harnessing TAMs for antibody-mediated cancer therapy, and demonstrate that this Fc switch approach may be broadly applicable to other targets in TAM-enriched tumor microenvironments.
Reddy et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: